A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices (Broad Effectiveness Trial With Aripiprazole- BETA)

Otsuka Pharmaceutical Development & Commercialization, Inc.1 site in 1 country1,200 target enrollmentSeptember 2002

ConditionsSchizophrenia

DrugsAripiprazole

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Schizophrenia
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Enrollment: 1200
Locations: 1
Primary Endpoint: Clinical Global Impression-Improvement at endpoint
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.

Registry

clinicaltrials.gov

Start Date

September 2002

End Date

November 2006

Last Updated

12 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Eligibility Criteria

Inclusion Criteria

•Clinical DSM-IV diagnosis of schizophrenia
•Patients being managed as outpatients, for whom an alteration in medication is clinically reasonable or initiation of antipsychotics is required

Exclusion Criteria

•Risk of committing suicide, diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic syptoms, or organic brain syndromes
•Prisoners or subjects compulsory detained